Academic Journal
P0979 Real-world effectiveness and safety of selective JAK inhibitors in ulcerative colitis and Crohn’s disease: A retrospective, mul-ticenter study
| العنوان: | P0979 Real-world effectiveness and safety of selective JAK inhibitors in ulcerative colitis and Crohn’s disease: A retrospective, mul-ticenter study |
|---|---|
| المؤلفون: | Farkas, B, Bessissow, T, Limdi, J K, Sethi-Arora, K, Kagramanova, A, Knyazev, O, Bezzio, C, Armuzzi, A, Lukas, M, Michalopoulos, G, Chaskova, E, Savarino, E V, Castiglione, F, Rispo, A, Schäfer, E, Saibeni, S, Filip, R, Attauabi, M, Fousekis, F S, Bacsur, P, Resál, T, Bálint, A, Ivány, E, Szepes, Z, Bősze, Z, Fábián, A, Bor, R, Farkas, K, Lakatos, P L, Molnár, T |
| المصدر: | Journal of Crohn's and Colitis ; volume 19, issue Supplement_1, page i1820-i1821 ; ISSN 1873-9946 1876-4479 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2025 |
| الوصف: | Background Data on the real-world effectiveness and safety of selective JAK inhibitors (JAKis) in ulcerative colitis (UC) and Crohn’s disease (CD) are limited. Methods We conducted a multicenter, retrospective study to assess clinical, biochemical, and endoscopic outcomes of selective JAKis in bio-experienced UC and CD patients. Corticosteroid-free clinical remission (CSFCR) was defined as clinical remission (CR; CDAI<150 in CD, and partial Mayo score ≤2 with a rectal bleeding subscore of 0 in UC) and not receiving local and systemic steroids ≥90 days before the assessment time point. Biochemical remission was defined as a serum C-reactive protein (CRP) level of ≤5 mg/L and a fecal calprotectin (FC) level of ≤150 µg/g. Endoscopic remission was defined as an endoscopic Mayo score of 0 in UC, and a Simple Endoscopic Score-CD of ≤4 points in CD patients. Therapeutic response was only assessed in patients who had the required data available at the specific time point („as observed analysis”). Multivariable logistic regression models were used to investigate predictors of CR at the end of the induction phase (at week 12 in CD, and at week 8 in UC patients). The potential impact of switching from tofacitinib to upadacitinib on therapeutic effectiveness was also assessed. Results 131 UC and 115 CD patients were included with a median follow-up of 7.5 months (Table 1.). Among the CD patients receiving upadacitinib (n=115), 76.2% achieved clinical remission (CR) at week 12. Furthermore, 59.5% of upadacitinib-treated UC patients (n=100) experienced CR at week 8. Corticosteroid-free CR (CSFCR) was achieved by 76.9% of CD patients and 80.6% of UC patients at week 24, while 50.0% and 36.1% experienced endoscopic remission. At week 52, 66.7% of CD and 86.2% of UC patients achieved CSFCR, whereas 54.5% and 52.9% had endoscopic remission. In UC, the effectiveness of upadacitinib was not compromised by prior tofacitinib failure, while upadacitinib-treated CD patients with stricturing and penetrating disease were ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/ecco-jcc/jjae190.1153 |
| الاتاحة: | https://doi.org/10.1093/ecco-jcc/jjae190.1153 https://academic.oup.com/ecco-jcc/article-pdf/19/Supplement_1/i1820/61546320/jjae190.1153.pdf |
| Rights: | https://academic.oup.com/pages/standard-publication-reuse-rights |
| رقم الانضمام: | edsbas.7AE118C3 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/ecco-jcc/jjae190.1153 |
|---|